Dambkowski Carl 4

What Happened

• Carl Dambkowski, a director of Oruka Therapeutics (ORKA), sold a total of 35,000 shares in two open‑market transactions: 22,417 shares on 2026-06-11 at a weighted average price of $70.13 for proceeds of $1,572,201, and 12,583 shares on 2026-06-12 at a weighted average price of $70.11 for proceeds of $882,182. Total proceeds were approximately $2,454,383. These were sales (not purchases), and therefore represent dispositions of existing holdings rather than new investments.

Key Details

• Transaction dates and reported weighted average prices:
  • 2026-06-11: 22,417 shares @ $70.13 = $1,572,201 (F3: prices ranged $70.00–$70.50)
  • 2026-06-12: 12,583 shares @ $70.11 = $882,182 (F2: prices ranged $70.00–$70.65)
• Total sold: 35,000 shares for ~$2.45M.
• Shares owned after transaction: Not specified in the information provided here — see the Form 4 for post‑transaction beneficial ownership.
• Notable footnotes:
  • F1: Sales were effected pursuant to a Rule 10b5‑1 trading plan entered on Feb 19, 2026 (pre‑scheduled trades).
  • F2/F3: Reported prices are weighted averages; multiple executions occurred within the stated ranges. The filer offers to provide a price‑by‑price breakdown on request.
• Filing timeliness: Form filed 2026-06-12 reporting transactions on 2026-06-11 and 2026-06-12; the filing does not indicate a late designation.

Context

• Sales under a Rule 10b5‑1 plan are typically pre‑arranged and do not necessarily indicate a change in the insider’s view of the company; they are generally considered routine. For retail investors, purchases often carry clearer signals than scheduled sales. For full details (including exact post‑trade holdings and any additional notes), review the Form 4 on the SEC site (Accession: 0000907654-26-000054).